Our Roundtables are by-invitation only meetings, held under Chatham House Rule. If you wish to be invited, please contact the Secretariat and we will review you request.
Chief Pharmacist, TLV; Co-Chair of the HTA Coordination Group
Senior Advisor HTA, FIPRA / RWE4Decisions Facilitator
Associate Director Real-World Evidence Methods, NICE
Senior Director, HEOR Oncology, Astellas
Member, Committee for Orphan Medicinal Products, European Medicines Agency; Data and AI Resource Manager, Microsoft
Director Science and Methods, Canada’s Drug Agency (CDA)
As artificial intelligence (AI) continues to transform healthcare, its integration into the analysis of real-world data (RWD) and the generation of real-world evidence (RWE) is reshaping how decisions are made across the health ecosystem.
Health Technology Assessment (HTA) and Payer bodies are increasingly recognising the potential of AI to enhance evidence generation, looking at how tools could be adopted to enhance the efficiency, accuracy, and scope of their evaluations. The UK’s National Institute for Health and Care Excellence (NICE) and Canada’s Drug Agency (CDA, formerly CADTH) have both released position statements that outline principles for the responsible use of AI in health technology assessments. These frameworks emphasise key pillars such as transparency, reproducibility, and the need for robust validation – especially when AI informs regulatory or reimbursement decisions.
Pharmaceutical companies are also leading this transformation, leveraging AI to streamline and strengthen evidence generation for HTA submissions. Applications include automating systematic literature reviews, optimising clinical trial design through predictive modelling, and enhancing patient selection. In the realm of RWE, AI is used to analyse unstructured data from electronic health records and clinical notes, uncovering insights into treatment effectiveness and patient outcomes. Additionally, AI supports the development of health economic models by structuring simulations and validating them against real-world data.
This RWE4Decisions webinar will spotlight these evolving dynamics and foster dialogue among diverse stakeholders. It aims to explore how technological innovation can be aligned with the needs and values of patients, clinicians, and decision-makers alike.
